Florida State University researchers are working on new approaches to deciphering genetic data that may lead to new, more targeted prostate cancer treatments. Prostate cancer, which affects one in ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, and University College London (UCL) today announced that data published online in ...

Genetic screening for prostate cancer can help identify inherited risks early, guide treatment decisions, and protect your family’s health. At Fred Hutch Cancer Center, we offer expert genetic ...

Prostate Cancer is the second leading cause of death in American men after lung cancer. In 2018, 165,000 men will be diagnosed with prostate cancer. The question all men with prostate cancer need ...

Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (VCYT) (Nasdaq: VCYT), a leading genomic ...

A genetic test developed by researchers at Broad Clinical Labs and the U.S. Department of Veterans Affairs (VA) is now enabling a large, nationwide clinical trial aimed at improving health care for ...

For Josh Henderson, 66, of Olympia, getting genetic testing was a no-brainer. “The first time I came to Fred Hutch, my oncologist suggested it,” said the retired IT manager who received a metastatic ...

Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...

The global statistics are terrifying. Prostate cancer is the fourth most common cancer in all populations, the second most common cancer among men worldwide, and ranks first in Europe, where a third ...

Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial “Our findings suggest that the Decipher Prostate test may provide an important new tool to help guide treatment decisions for the ...